PMID- 20059535
OWN - NLM
STAT- MEDLINE
DCOM- 20100628
LR  - 20100607
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 84
IP  - 5
DP  - 2010 May
TI  - Free light chain: a novel predictor of adverse outcome in chronic lymphocytic 
      leukemia.
PG  - 406-11
LID - 10.1111/j.1600-0609.2010.01412.x [doi]
AB  - OBJECTIVES: Chronic lymphocytic leukemia (CLL) is characterized by a highly 
      variable clinical course. This retrospective study is planned to assess the 
      prognostic value of serum free light chain (sFLC) levels and FLC ratio (FLCR) in 
      CLL. METHODS: Quantitative levels of sFLC were measured nephelometrically in sera 
      collected at diagnosis. The expressions of ZAP70 and CD38 were quantified by flow 
      cytometry. Chromosomal abnormalities were determined by interphase fluorescence 
      in situ hybridization (FISH). RESULTS: In a cohort of 101 patients with a median 
      follow-up of 29 (1-234) months, sFLC levels were found to be high in 55 patients 
      (54.5%). An abnormal FLCR was found in 30 patients (29.7%). FISH-based genetic 
      risk groups did not differ significantly with respect to sFLC and FLCR (P > 
      0.05). Median time to first treatment was shorter in patients with high sFLC 
      levels (P = 0.02). Median overall survival (OS) was shorter in patients with high 
      sFLC levels (P = 0.01) and abnormal FLCR (P = 0.05). In patients with early stage 
      disease, median OS was shorter in high sFLC (P = 0.03) and abnormal FLCR groups 
      (P = 0.048). A relationship was observed between abnormal sFLC levels and CD38 
      positivity on logistic regression analysis (P = 0.003; OR: 4.44; 95% CI: 
      1.66-11.8). CONCLUSIONS: This study highlighted the adverse prognostic impact of 
      high sFLC levels and abnormal FLCR with regard to survival in CLL, even in early 
      stage patients. Prospective studies are warranted to validate the adverse impact 
      of sFLC and FLCR on clinical outcome.
FAU - Yegin, Zeynep A
AU  - Yegin ZA
AD  - Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey. 
      zyegin@gazi.edu.tr
FAU - Ozkurt, Zubeyde N
AU  - Ozkurt ZN
FAU - Yagci, Munci
AU  - Yagci M
LA  - eng
PT  - Journal Article
DEP - 20100105
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Immunoglobulin Light Chains)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunoglobulin Light Chains/*blood
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/blood/*immunology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Survival Rate
EDAT- 2010/01/12 06:00
MHDA- 2010/06/29 06:00
CRDT- 2010/01/12 06:00
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2010/06/29 06:00 [medline]
AID - EJH1412 [pii]
AID - 10.1111/j.1600-0609.2010.01412.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2010 May;84(5):406-11. doi: 10.1111/j.1600-0609.2010.01412.x. 
      Epub 2010 Jan 5.